284P - Patient reported pain severity and interference in HR + /HER2- advanced/metastatic breast cancer in real world settings

Abstract

To assess patient reported pain severity and pain interference in HR + /HER2- advanced/metastatic breast cancer (ABC/MBC) across multiple countries in a real world setting. Physicians across 5 major EU countries and the US participated in a cross-sectional study of over 2000 patients with HR + /HER2- ABC/MBC. A subset of patients (N = 739) completed validated questionnaires, including the Brief Pain Inventory (BPI), used to assess the severity and impact of pain on daily functions. Pain severity is reported at its worst on a 0-10 scale, while average pain severity is a mean of 4 items on a 0-10 scale (worst & least in past 24 hours, average and current pain). On both scales a higher score implies greater pain. Interference is a mean of 7 items on a 0-10 scale with higher scores implying greater pain interference. Mean scores are reported for the overall cohort and by sites of metastases and compared using Mann-Whitney U and Kruskal-Wallis tests. Mean (SD) scores for worst pain was 3.1 (2.4), average pain was 2.4 (1.9), and pain interference was 2.8 (2.2). The subgroup with bone and visceral metastases had significantly higher (p < 0.05) average pain severity [3.0 (1.9)], compared to those with bone disease (no visceral metastases) [2.5 (1.9)] and those with visceral (no bone) disease [2.2 (1.9)]. Pain interference was significantly higher (p < 0.05) for those with both bone and visceral metastases (3.4 [2.2]) followed by bone disease (2.9 [2.1]) and visceral disease (2.6 [2.2]). In a subset of patients receiving chemotherapy at the time of completion of the BPI, worst pain was significantly (p < 0.05) higher in patients with both metastases [3.8 (2.4)], compared to those with bone metastases [3.4 (2.3)] and those with visceral metastases [2.8 (2.3)]. No significant difference in pain interference scores were observed by type of metastatic site within the subset of patients treated with chemotherapy. Low to moderate levels of pain severity and pain interference scores observed in advanced/metastatic breast cancer patients in the real world, which vary significantly by extent and site of metastases.